EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access

Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Ghayas C Issa iD, Ibrahim Aldoss, Michael J Thirman iD, John DiPersio iD, Martha Arellano, James S Blachly iD, Gabriel N Mannis, Alexander Perl iD, David S Dickens iD, Christine M McMahon, Elie Traer iD, C Michel Zwaan iD und 15 weitere

Journal of Clinical Oncology · 2025-01 · 43 (1) · 75-84

DOI: 10.1200/jco.24.00826 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2025-01. Verfasst von Ghayas C Issa und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase, Myeloid-Lymphoid Leukemia Protein, Leukemia, Myeloid, Acute, Nucleophosmin. Die Arbeit wurde bisher 272-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with KMT2A -rearranged ( KMT2Ar ) acute leukemia. Here, we evaluated the activity of revumenib in individuals with relapsed/refractory (R/R) KMT2Ar acute leukemia. METHODS AUGMENT-101 is a phase I/II, open-label, dose-escalation and expansion study of revumenib conducted across 22 clinical sites in five countries (ClinicalTrials.gov identifier: NCT04065399 ). We report results from the phase II, registration-enabling portion. Individuals age ≥30 days with R/R KMT2Ar acute leukemia or with AML and nucleophosmin 1 ( NPM1 ) mutation were enrolled. Revumenib was administered once every 12 hours, at 163 mg (95 mg/m 2 if weight

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinLeukemia, Myeloid, AcuteNucleophosminProto-Oncogene ProteinsHumansMiddle AgedAdultMaleFemaleAgedYoung AdultAdolescentGene RearrangementBenzamidesSpiro Compounds

Substanzen

Histone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinKMT2A protein, humanMEN1 protein, humanNucleophosminNPM1 protein, humanProto-Oncogene ProteinsrevumenibBenzamidesSpiro Compounds

Autor:innen und Institutionen

  • Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
  • Biological Sciences Division, The University of Chicago Medicine, Chicago, IL.
  • John T. Milliken Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO.
  • Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
  • Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH.

ORCID-Profile: Ghayas C Issa, Michael J Thirman, John DiPersio, James S Blachly, Alexander Perl, David S Dickens, Elie Traer, C Michel Zwaan, Carolyn S Grove, Richard Stone, Matthew Greenwood, Neerav Shukla, Eytan M Stein

Förderung

  • NCI NIH HHS

Zitieren

APA

Issa, G. C., Aldoss, I., Thirman, M. J., DiPersio, J., Arellano, M., Blachly, J. S., Mannis, G. N., Perl, A., Dickens, D. S., McMahon, C. M., Traer, E., Zwaan, C. M., Grove, C. S., Stone, R., Shami, P. J., Mantzaris, I., Greenwood, M., Shukla, N., Cuglievan, B., …, & Stein, E. M. (2025). Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Journal of Clinical Oncology, 43(1), 75-84. https://doi.org/10.1200/jco.24.00826

Vancouver

Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Journal of Clinical Oncology. 2025;43(1):75-84. doi:10.1200/jco.24.00826

BibTeX
@article{Issa2025,
  author = {Issa, Ghayas C and Aldoss, Ibrahim and Thirman, Michael J and DiPersio, John and Arellano, Martha and Blachly, James S and Mannis, Gabriel N and Perl, Alexander and Dickens, David S and McMahon, Christine M and Traer, Elie and Zwaan, C Michel and Grove, Carolyn S and Stone, Richard and Shami, Paul J and Mantzaris, Ioannis and Greenwood, Matthew and Shukla, Neerav and Cuglievan, Branko and Kovacsovics, Tibor and Gu, Yu and Bagley, Rebecca G and Madigan, Kate and Chudnovsky, Yakov and Nguyen, Huy Van and McNeer, Nicole and Stein, Eytan M},
  title = {Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {1},
  pages = {75--84},
  doi = {10.1200/jco.24.00826}
}
Kostenlos starten →